Cinven's co-private equity directors say it's time to move on
Those in charge of one of the largest private equity firms in Europe argue that the new focus on regulation will prevent problems like the illegal price hikes to the UK's National Health Service from recurring.
Cinven, a major European private equity firm, is working to restore stability after a period of turmoil, including a scandal in which a pharmaceutical company owned by Cinven illegally increased prices sold to the UK's National Health Service (NHS). The firm's co-directors, Jorge Quemada and Bruno Schick, say they have implemented new measures to ensure compliance with regulations, including training teams and creating an internal legal and compliance team.
Cinven has also changed its approach to sharing profits with employees, making lucrative carried interest payments available to all staff, not just investment professionals. The firm is nearing the close of a €1,500 million fund focused on mid-sized acquisitions and is expected to launch its next large fundraising round next year.
Written by urgent.news from Expansion ES's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
